Global In-Vivo CAR-T Therapeutics Market - Trends and Forecast Till 2035

IN-VIVO CAR-T THERAPEUTICS MARKET: OVERVIEW

The global in-vivo CAR-T therapeutics market is estimated to grow from USD 0.86 billion in the current year to USD 10.84 billion by 2035, registering a CAGR of 32.5% across the forecast period.

In-Vivo CAR-T Market: Growth and Trends

In-vivo CAR-T therapeutics have emerged as one of the fastest-evolving frontiers in cell and gene therapy, marking a significant shift from conventional ex-vivo approaches. The field initially comprised a cohort of platform-focused biotechs, including Capstan Therapeutics, Interius BioTherapeutics, Orna Therapeutics, Kelonia Therapeutics, EsoBiotec, Orbital Therapeutics, and Umoja Biopharma. However, the competitive landscape is rapidly consolidating as major pharmaceutical companies including AbbVie, Gilead (Kite), Bristol Myers Squibb, AstraZeneca, and Eli Lilly secure in-vivo CAR-T delivery technologies through acquisitions and licensing partnerships.

Viral-vector platforms, particularly lentiviral systems developed by companies such as Umoja, Interius, EsoBiotec, and Kelonia, currently represent the largest share of pipeline activity due to their durable gene delivery capabilities. In contrast, non-viral platforms based on LNP-formulated mRNA or circular RNA, including approaches pursued by Capstan, Orna, and Orbital, are gaining momentum rapidly, supported by their re-dosing potential, scalable manufacturing economics, and suitability for chronic autoimmune diseases where permanent genetic integration may be less desirable.

While early in-vivo CAR-T programs targeted CD19- and BCMA-driven hematologic malignancies, several leading candidates are now advancing into B-cell-mediated autoimmune diseases such as lupus and systemic sclerosis, a shift that materially broadens the addressable patient population and commercial opportunity relative to first-generation ex-vivo CAR-T therapies.

Growth Drivers: Factors Fueling Market Expansion

The in-vivo CAR-T therapeutics market is being driven by the potential to eliminate costly and time-intensive ex-vivo cell manufacturing, reducing treatment from a multi-week process to a single infusion-based intervention. By removing the need for patient-specific leukapheresis and specialized cleanroom manufacturing, these platforms could lower per-patient costs and expand CAR-T access beyond the limited number of centers currently equipped to deliver autologous cell therapies.

Rising global cancer incidence, an expanding base of clinical trials evaluating in-vivo constructs, and continued technological refinement of lentiviral, AAV, and LNP delivery systems including improved cell-type targeting ligands and reduced off-target biodistribution are reinforcing the growth trajectory. Sustained big-pharma validation is further strengthening the in-vivo CAR-T therapeutics market, with more than USD 15 billion in disclosed acquisition and licensing commitments since early 2025. This heightened strategic interest is also driving capital toward early-stage platform companies and specialized CDMOs focused on viral-vector and LNP manufacturing capabilities.

Market Challenges: Critical Barriers Hindering Progress

Despite favorable growth prospects, the in-vivo CAR-T therapeutics market faces several barriers that could temper near-term commercial progress. Viral-vector platforms must manage pre-existing immunity and anti-vector immune responses that can blunt in-vivo transduction efficiency, while non-viral LNP platforms face open questions around achieving sufficiently durable and cell-type-specific gene expression outside the liver. Manufacturing at commercial scale for GMP-grade lentiviral vectors and LNP-formulated RNA remains capital-intensive and supply-constrained. Further, regulatory pathways for in-vivo gene delivery platforms are still being defined by agencies as long-term durability, re-dosing, and off-target editing safety data accumulate. Addressing these technical, manufacturing, and regulatory challenges will be central to converting early clinical proof-of-concept into approved, reimbursed therapies.

In-Vivo CAR-T Therapeutics Market: Key Insights

This report examines the current state of the global in-vivo CAR-T therapeutics market and identifies the growth opportunities available to biopharmaceutical innovators, CDMOs, and investors. Some of the key findings include:

• Lentiviral vector-based platforms currently anchor the largest share of the clinical-stage in-vivo CAR-T pipeline, though non-viral LNP-mRNA and circular RNA platforms are the fastest-growing delivery category given their re-dosing potential and applicability to autoimmune indications.
• North America leads the global market on the strength of concentrated clinical trial activity, dense biopharma and CDMO infrastructure, and early regulatory engagement, while Asia-Pacific’s higher CAGR is supported by China's expanding cell and gene therapy manufacturing base.
• CD19- and BCMA-targeted programs dominate current clinical activity in B-cell malignancies and multiple myeloma respectively, while CD20 and CD22 constructs are advancing as differentiated or combination options, and autoimmune-focused CD19 programs are emerging as a distinct, high-growth indication category.
• Since March 2025, big pharma has committed more than USD 17 billion in disclosed acquisition and partnership value to in-vivo CAR-T platforms, consolidating a previously fragmented field of venture-backed biotechs into a small number of pharma-owned delivery platforms.
• Specialty viral vector and LNP manufacturing capacity, along with GMP-grade plasmid, mRNA, and lipid-component supply, represents a critical near-term bottleneck and a corresponding opportunity for CDMOs and raw-material suppliers positioning around this modality.
• The competitive field has organized into distinct technology camps, such as lentiviral integration platforms, LNP-mRNA and circular RNA platforms, and hybrid enveloped delivery vehicle (EDV) systems each carrying different manufacturing, durability, and regulatory profiles that will shape licensing and M&A activity over the next 12-24 months.

Global In-Vivo CAR-T Therapeutics Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Delivery Platform

• Viral Vector-Based
• Lentiviral Vectors
• Adeno-Associated Virus (AAV)
• Non-Viral
• LNP-mRNA
• Circular RNA
• Other Non-Viral Systems
• Hybrid / Enveloped Delivery Vehicle (EDV) Platforms

By Target Antigen

• CD19
• CD20
• CD22
• BCMA
• Other Targets

By Route of Administration

• Systemic (Intravenous) Delivery
• Localized (Intratumoral) Delivery

By Therapeutic Area

• Oncological Disorders (Hematologic Malignancies)
• Autoimmune Disorders
• Other Indications

By End User

• Hospitals
• Specialty Care Centers
• Academic and Research Institutes

By Geographical Regions

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia-Pacific
• Middle East and North Africa
• Saudi Arabia
• UAE
• Latin America
• Brazil
• Argentina
• Rest of Latin America

In-Vivo CAR-T Therapeutics Market: Key Segment Insights

Viral Vector Platforms Lead Current Delivery Share

Lentiviral vector-based delivery currently accounts for the largest share of the market. This highest share is supported by a well-characterized safety and manufacturing track record inherited from ex-vivo CAR-T and broader gene therapy programs. Non-viral LNP-mRNA and circular RNA platforms represent the fastest-growing delivery category as developers prioritize re-dosable non-integrating constructs suited to chronic autoimmune disease treatment.

Localized Delivery Is the Fastest-Growing Route of Administration

According to the Roots Analysis market report, localized, intratumoral delivery accounted for the largest market share and is projected to register the fastest growth through 2035. This dual dominance reflects the approach’s ability to deliver therapeutic constructs directly into the tumor microenvironment, thereby increasing local drug exposure and enhancing antitumor activity while potentially reducing systemic exposure and treatment-related toxicity compared with intravenous administration. The resulting combination of higher tumor-site concentration, improved therapeutic precision, and a potentially more favorable safety profile is expected to support continued adoption of intratumoral delivery approaches.

Hospitals Dominate the End-User Landscape

According to our projection, hospitals held the highest market share and are likely to remain dominant in the future. This largest share reflects their role as the primary setting equipped for advanced-therapy administration, multidisciplinary patient management, and management of cytokine release syndrome and neurotoxicity risk associated with CAR-T mechanisms of action.

North America Leads; Asia-Pacific Set for Fastest Growth

North America is expected to maintain its position as the leading regional market through 2035. This dominance is supported by a strong concentration of in-vivo CAR-T developers, clinical research infrastructure, and specialized viral-vector and LNP manufacturing capabilities in the US. Asia-Pacific is projected to record the fastest CAGR, driven primarily by China’s expanding cell and gene therapy ecosystem, increasing manufacturing capacity, and rising clinical trial activity.

Example Players in the In-Vivo CAR-T Therapeutics Market

• AbbVie (Capstan Therapeutics)
• AstraZeneca (EsoBiotec)
• Beam Therapeutics
• Bristol Myers Squibb (Orbital Therapeutics)
• Cellectis
• CRISPR Therapeutics
• Eli Lilly and Company (Orna Therapeutics, Kelonia Therapeutics)
• Gilead Sciences / Kite Pharma (Interius BioTherapeutics)
• Intellia Therapeutics
• Legend Biotech
• Myeloid Therapeutics
• Novartis
• Poseida Therapeutics
• Precision BioSciences
• Pregene Biopharma
• Sana Biotechnology
• Umoja Biopharma
• Vyriad

IN-VIVO CAR-T THERAPEUTICS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: In-depth analysis across delivery platform, target antigen, route of administration, therapeutic area, end user, and geography.
• Competitive Landscape: A detailed assessment of active in-vivo CAR-T developers, including platform technology, pipeline stage, and ownership status following recent M&A activity.
• Company Profiles: Profiles of prominent players, covering platform overview, pipeline, recent financing/M&A history, and strategic partnerships.
• Technology Benchmarking: Comparative assessment of lentiviral, AAV, LNP-mRNA, circular RNA, and hybrid EDV delivery platforms across manufacturing complexity, durability, re-dosability, and safety profile.
• Pipeline Analysis: Clinical and preclinical pipeline mapped by phase of development, target antigen, indication, and sponsor.
• Partnerships and Collaborations: Analysis of licensing deals, co-development agreements, and other partnerships by year, deal type, and platform.
• Funding and M&A Analysis: A detailed review of venture financing, acquisitions, and licensing transactions, including deal value, structure, and most active acquirers.
• SWOT Analysis: Strategic assessment of strengths, weaknesses, opportunities, and threats facing in-vivo CAR-T developers and delivery-platform licensors.

KEY QUESTIONS ANSWERED IN THIS REPORT

• Which companies and delivery platforms are leading the in-vivo CAR-T therapeutics market?
• Which region dominates the market today, and which region is growing the fastest?
• What are the key technology and clinical trends shaping this market?
• What factors are likely to influence the evolution of the in-vivo CAR-T market?
• What are the primary technical, manufacturing, and regulatory challenges facing developers?
• What is the current and projected future size of the in-vivo CAR-T therapeutics market?
• What is the CAGR of this market through 2035?
• How is current and future market opportunity distributed across delivery platform, target antigen, and therapeutic area?
• What licensing, partnership, and acquisition opportunities exist for pharmaceutical companies and investors entering this space?

REASONS TO BUY THIS REPORT

This report is designed to give biopharmaceutical companies, investors, and manufacturing partners a decisive analytical edge in a fast-consolidating market. Its core differentiators include:

• Top-Down and Bottom-Up Triangulated Forecasting: Market estimates are built using a hybrid methodology that cross-validates top-down macro assessments against bottom-up, platform-level pipeline and deal data to minimize forecast bias.
• M&A and Licensing Deal Lens: Unlike conventional cell therapy landscape reports, this study maps the full wave of in-vivo CAR-T acquisitions and licensing deals, and the strategic logic behind each major pharma's platform bet.
• Technology Platform Benchmarking: Comparative evaluation of lentiviral, AAV, LNP-mRNA, circular RNA, and hybrid delivery systems, supporting technology diligence for in-licensing, partnership, or in-house platform investment decisions.
• Primary Research-Backed Insights: Findings are informed by review of company disclosures, clinical trial data, and deal documentation, ensuring insights reflect real development and commercial conditions.
• Actionable Segmentation: Multi-parameter segmentation (delivery platform, target antigen, route of administration, therapeutic area, end user, geography) enables precise opportunity sizing for any go-to-market, licensing, or investment thesis.

ADDITIONAL BENEFITS

• Complementary data packs covering key market segments
• Content customization available on request
• Detailed report walkthrough session with the research team
• Free report update if the report is 6-12 months old or older